Stay updated on Lazertinib Combination in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lazertinib Combination in NSCLC Clinical Trial page.

Latest updates to the Lazertinib Combination in NSCLC Clinical Trial page
- Check3 days agoChange DetectedAdded a Publications entry for the CHRYSALIS-2 Cohort A paper with full author details. Corrected the Köln collaborator location by replacing the misspelled entry with the proper 'Kliniken der Stadt Köln gGmbH, Krankenhaus Köln-Mehrheim' and removed the erroneous version.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page's revision line was updated from v3.5.2 to v3.5.3. This indicates a new revision of the page content.SummaryDifference0.0%

- Check25 days agoChange DetectedThe page footer revision label was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check32 days agoChange DetectedThe study record shows updates in April 2026, with the latest posting dated 2026-04-13. These changes appear to be metadata updates rather than substantive changes to the study's design or results.SummaryDifference0.1%

- Check54 days agoChange DetectedLocation entries were updated to reflect language and postcode corrections. Boston, MA 02115 and Naples, Italy 80131 were added, while Boston 02215 and Napoli 80131 were removed.SummaryDifference0.3%

- Check69 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Lazertinib Combination in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib Combination in NSCLC Clinical Trial page.